12CQ chip
The 12CQ is Archer's carbon-based quantum chip designed to operate at higher temperatures than conventional processors — no cryogenic cooling. ASX: AXE.

Archer Materials is a quantum technology company developing the 12CQ quantum computing chip and a medical diagnostics biochip.
archerx.com.auCrawled Nov 16, 2026
The 12CQ is Archer's carbon-based quantum chip designed to operate at higher temperatures than conventional processors — no cryogenic cooling. ASX: AXE.
Archer's graphene biochip detects potassium in blood for chronic kidney disease monitoring. Point-of-care finger-prick test. Results in minutes.
Archer and IonQ: quantum computing access, commercial applications and a pathway to sovereign quantum capability for Australian organisations. ASX: AXE.
Archer develops the 12CQ quantum chip for computing and sensing, and the Archer Biochip for kidney disease diagnostics. Both built on graphene. ASX: AXE.
A Business Leader's Guide To Quantum Technology | Archer Materials (ASX: AXE)
A Quantum Advantage in Fighting Climate Change | Archer Materials (ASX: AXE)
A quantum computing tipping point | Archer Materials (ASX: AXE)
Deep tech, machine learning and artificial intelligence | Archer Materials (ASX: AXE)
Ensuring online security in a quantum future | Archer Materials (ASX: AXE)
Even Einstein Found Quantum Mechanics ‘Spooky' | Archer Materials (ASX: AXE)
Archer Materials on the 2025 Nobel Prize in Physics — awarded to quantum pioneers and why this matters for Australia's quantum computing industry. AXE.
Archer Materials advances as a pure-play deep tech company, focused on two hardware programs: the 12CQ quantum chip and graphene Biochip. ASX: AXE.
Archer Materials and IBM sign a quantum computing agreement, deepening Archer's access to global quantum research and hardware expertise. ASX: AXE.
Archer Materials and Max Kelsen expand their partnership on quantum machine learning applications, following the CSIRO QML fraud detection program.
Archer Materials attends Quantum Australia 2024, presenting research contributions and engaging with Australia's growing quantum technology community. AXE.
Archer’s newsroom provides updates on company news, press releases, and media coverage of its quantum technology and biochips.
Join Archer Materials (ASX: AXE) in Sydney. Open roles in quantum engineering and biomedical engineering at Australia's leading quantum hardware company.
The page introduces Archer Materials’ board and executive team, including CEO Dr. Simon Ruffell and Executive Chairman Greg English.
Andrew Just is a Non-Executive Director at Archer Materials (ASX: AXE), with 30 years in global MedTech across GE Healthcare, Stryker, and Cochlear.
Bernadette Harkin is a Non-Executive Director at Archer Materials (ASX: AXE). 20+ years in enterprise technology across IBM, Avanade, and CGI.
Clarissa Driver is Head of People & Operations at Archer Materials (ASX: AXE) and Co-Chair of the Australian Quantum Alliance. 20+ years in technology.
Dr Andrew Sexton heads engineering at Archer Materials (ASX: AXE), leading both the 12CQ quantum chip and Biochip programs. PhD, University of Limerick.
Dr David Vander is Quantum Business Executive at Archer Materials (ASX: AXE). Ex-Microsoft and Salesforce, former CEO of LiveTiles. PhD in Business Strategy.
Archer Materials (ASX: AXE) builds quantum technologies for computing, sensing, and healthcare. Patented IP across North America, APAC, and Europe.
Corporate governance documents for Archer Materials (ASX: AXE) including Board Charter, committee charters, and ASX compliance policies.
Contact Archer Materials (ASX: AXE). Offices in Sydney and Adelaide. General enquiries: hello@archerx.com.au. Media enquiries: +61 8 7095 3288.
Archer Materials (ASX: AXE) develops the 12CQ quantum chip and a graphene biochip for kidney disease diagnostics. An Australian quantum technology company.
Archer Materials appoints David Vander as the leader of its quantum commercialization efforts. The move aims to accelerate the company’s push into practical applications of quantum technologies. Vander brings expertise in scaling advanced materials for industrial use.
Archer Materials is expanding its partnership with IonQ to advance quantum computing applications. The company also launches a national commercial pilot program for quantum technologies in the first quarter of fiscal year 2027. Both initiatives aim to accelerate the practical deployment of quantum solutions in Australia.
Archer Materials secures AU$7 million ($4.9 million) in funding to advance its quantum computing partnership with IonQ. The capital supports development of sovereign quantum services in Australia, aligning with the technical and strategic terms of the IonQ collaboration.
Archer Materials partners with IonQ to explore on-shore sovereign deployment of quantum computing and scale quantum machine learning (QML) applications in capital markets. The three-year agreement grants Archer access to IonQ’s Quantum Cloud platform, featuring high-fidelity trapped-ion hardware, to expand beyond graphene-based chip development into end-to-end quantum services. The US$1.5 million deal supports Archer’s transition into a sovereign quantum computing operator.
Archer Materials partners with IonQ to advance quantum computing technologies. The Australian company develops solutions in quantum computing, sensing, and medical diagnostics. This agreement formalizes a collaboration to integrate IonQ’s quantum processing capabilities into Archer’s product pipeline.
Archer Materials progresses its Biosensor beta prototype toward preclinical validation, aiming for external testing and 2027 clinical trials. The company collaborates with IMEC to refine the sensor technology for future medical applications.
Archer Materials develops a 12-qubit (12CQ) chip, advancing its quantum computing technology. The milestone places the company among leaders in quantum hardware innovation. Archer’s progress focuses on scaling qubit capacity for potential commercial and research applications.